Skip to main content

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Jan. 6, 2015, 67 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $228.16 to $2,641,920.00.

Highlighted Stocks Traded by Insiders:

RPX (RPXC) - FREE Research Report

Segal Ned D., who is Chief Financial Officer, SVP at RPX, sold 4,500 shares at $13.63 on Jan. 6, 2015. Following this transaction, the Chief Financial Officer, SVP owned 32,410 shares meaning that the stake was reduced by 12.19% with the 4,500-share transaction.

The shares most recently traded at $13.53, down $0.10, or 0.75% since the insider transaction. Historical insider transactions for RPX go as follows:

  • 4-Week # shares sold: 20,000
  • 12-Week # shares sold: 76,506
  • 24-Week # shares bought: 10,000
  • 24-Week # shares sold: 167,869

The average volume for RPX has been 301,700 shares per day over the past 30 days. RPX has a market cap of $733.0 million and is part of the services sector and diversified services industry. Shares are down 1.6% year-to-date as of the close of trading on Tuesday.

RPX Corporation provides patent risk management solutions in the United States, Japan, and internationally. It offers a subscription-based patent risk management solution that facilitates exchanges of value between owners and users of patents. The company has a P/E ratio of 20.0. Currently, there are 2 analysts who rate RPX a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on RPXC - FREE

TheStreet Quant Ratings

rates RPX as a

buy

Scroll to Continue

TheStreet Recommends

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, expanding profit margins and growth in earnings per share. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full

RPX Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Anacor Pharmaceuticals (ANAC) - FREE Research Report

Maples Kirk R, who is SVP, Program Management at Anacor Pharmaceuticals, sold 600 shares at $31.96 on Jan. 6, 2015. Following this transaction, the SVP, Program Management owned 4,200 shares meaning that the stake was reduced by 12.5% with the 600-share transaction.

The shares most recently traded at $31.63, down $0.33, or 1.03% since the insider transaction. Historical insider transactions for Anacor Pharmaceuticals go as follows:

  • 4-Week # shares sold: 61,248
  • 12-Week # shares sold: 62,448
  • 24-Week # shares sold: 77,809

The average volume for Anacor Pharmaceuticals has been 517,600 shares per day over the past 30 days. Anacor Pharmaceuticals has a market cap of $1.4 billion and is part of the health care sector and drugs industry. Shares are down 0.81% year-to-date as of the close of trading on Tuesday.

Anacor Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. The company has a P/E ratio of 21.9. Currently, there are 3 analysts who rate Anacor Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ANAC - FREE

TheStreet Quant Ratings

rates Anacor Pharmaceuticals as a

hold

. The company's strengths can be seen in multiple areas, such as its notable return on equity, good cash flow from operations and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income and feeble growth in the company's earnings per share. Get the full

Anacor Pharmaceuticals Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Citizens and Northern (CZNC) - FREE Research Report

Fisher Jan E, who is Director at Citizens and Northern, bought 299 shares at $20.81 on Jan. 6, 2015. Following this transaction, the Director owned 14,081 shares meaning that the stake was boosted by 2.17% with the 299-share transaction.

Mattie Raymond R, who is Director at Citizens and Northern, bought 239 shares at $20.81 on Jan. 6, 2015. Following this transaction, the Director owned 21,731 shares meaning that the stake was boosted by 1.11% with the 239-share transaction.

The shares most recently traded at $20.46, down $0.35, or 1.7% since the insider transaction. Historical insider transactions for Citizens and Northern go as follows:

  • 4-Week # shares bought: 150
  • 4-Week # shares sold: 1,500
  • 12-Week # shares bought: 192
  • 12-Week # shares sold: 1,500
  • 24-Week # shares bought: 2,117
  • 24-Week # shares sold: 2,259

The average volume for Citizens and Northern has been 23,500 shares per day over the past 30 days. Citizens and Northern has a market cap of $253.8 million and is part of the financial sector and banking industry. Shares are down 0.1% year-to-date as of the close of trading on Tuesday.

Citizens & Northern Corporation operates as the bank holding company for Citizens & Northern Bank that provides a range of banking and mortgage services to individual and corporate customers in North Central Pennsylvania and Southern New York. The stock currently has a dividend yield of 5.04%. The company has a P/E ratio of 15.2. Currently, there are no analysts who rate Citizens and Northern a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CZNC - FREE

TheStreet Quant Ratings

rates Citizens and Northern as a

buy

. The company's strengths can be seen in multiple areas, such as its expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had somewhat weak growth in earnings per share. Get the full

Citizens and Northern Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null